Kindstar Globalgene Technology Inc
09960
Company Profile
Business description
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.
Contact
Biolake D2-1, 666 Gaoxin Road
East Lake High Tech Zone
Hubei Province
Wuhan
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
3,011
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.90 | 2.50 | -0.03% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
| NZX 50 Index | 13,244.82 | 36.32 | -0.27% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |